Emond C, Pécher C, Bascands J L, Regoli D, Girolami J P
INSERM U133, Institut Louis Bugnard, Faculté de Médecine Rangueil, Toulouse, France.
Agents Actions Suppl. 1992;38 ( Pt 2):390-7.
We have recently characterized a bradykinin (BK) receptor in rat renal mesangial cells (1). Activation of this receptor is associated with PGE2 release and IP3 formation suggesting involvement in cell contraction which can be linked to the control of the glomerular filtration rate (2). Whether this mesangial BK receptor is the unique glomerular BK receptor remains to be elucidated. In an attempt to answer to this question, we performed binding studies using decapsulated isolated glomeruli. Scatchard analysis of the binding data obtained with this preparation revealed the presence of two distinct B2-kinin binding sites. However, a consistent difference was observed in both the affinity and the density. We further investigated the pharmacological binding profile after an initial step of solubilization. Several experiments were performed to establish optimal conditions of solubilization. For this, different detergents such as Triton X-100, CHAPS and n-octyl beta-D glucopyranoside were tested at various concentrations, durations and temperatures of incubation. The binding was performed with two different [125I]-Tyr0-BK concentrations (0.5 and 7 nM) with either untreated decapsulated glomeruli or solubilized preparation for 45 minutes at +4 degrees C in the binding buffer containing a mixture of protease inhibitors. The greatest binding was achieved after treating glomeruli with 25 mM n-octyl beta-D glucopyranoside for 60 minutes at +4 degrees C under constant shaking. Two B2-kinin receptors of different affinities were detected. The same binding characteristics were obtained both in the 12,000 x g and 100,000 x g supernatant.(ABSTRACT TRUNCATED AT 250 WORDS)
我们最近对大鼠肾系膜细胞中的缓激肽(BK)受体进行了特性描述(1)。该受体的激活与前列腺素E2释放和肌醇三磷酸形成相关,提示其参与细胞收缩,这可能与肾小球滤过率的控制有关(2)。这种系膜BK受体是否是唯一的肾小球BK受体仍有待阐明。为了回答这个问题,我们使用去包膜的分离肾小球进行了结合研究。对该制剂获得的结合数据进行Scatchard分析,发现存在两个不同的B2-激肽结合位点。然而,在亲和力和密度方面均观察到一致的差异。在初步溶解步骤后,我们进一步研究了药理学结合谱。进行了多项实验以确定最佳溶解条件。为此,测试了不同的去污剂,如Triton X-100、CHAPS和正辛基-β-D-葡萄糖苷,在不同浓度、孵育时间和温度下进行测试。结合实验使用两种不同浓度(0.5和7 nM)的[125I]-酪氨酸0-缓激肽,分别与未处理的去包膜肾小球或溶解制剂在含有蛋白酶抑制剂混合物的结合缓冲液中于+4℃孵育45分钟。在+4℃下用25 mM正辛基-β-D-葡萄糖苷处理肾小球60分钟并持续摇晃后,获得了最大结合量。检测到两种不同亲和力的B2-激肽受体。在12,000×g和100,000×g的上清液中均获得了相同的结合特性。(摘要截断于250字)